Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience

Table 1 Clinical and laboratory characteristics at baseline

Variables	Case1	Case2	Case3	Case4	Case5	Case6	Case7	Case8	Case9	Case10	Case11
Sex	F	F	M	M	F	M	F	F	F	M	F
Age at disease onset (years)	3.67	9.5	3.33	3.58	1.92	4.42	3.92	5.42	6	1.58	9.1
Age at diagnosis (years)	4.25	9.5	3.42	6.58	2	4.42	4.1	5.42	6	2	9.25
Time from onset to receiving canakinumab (months)	9	9	15	100	48	45	42	23	37	148	69
Number of joints with active inflammation	10	2	6	1	3	3	0	2	12	21	5
Fever	+	_	+	+	+	+	+	+	_	_	_
Rash	_	_	_	_	_	+	+	+	_	_	_
Lymphadenopathy	+	_	_	+	_	+	_	_	_	_	_
Myalgia	+	+	_	_	_	+	_	_	_	_	_
Previous MAS	_	_	_	_	+	_	+	+	_	_	_
Ferritin > 330 ng/mL	+	_	+	+	+	+	_	_	_	+	_
WBC > 15,000/mm³	+	+	+	+	+	+	+	+	_	_	+
ESR > 20 mm/h	+	_	+	+	+	_	+	+	+	+	+
CRP > 10 mg/L	+	_	+	+	+	+	+	+	+	+	+
Increased transaminases	_	_	_	_	_	+	_	_	_	_	_

F Female, M Male, MAS Macrophage activation syndrome, WBC White blood cell, ESR Erythrocyte sedimentation rate, CRP C-reactive protein

ISSN: 1546-0096